Niagen Bioscience (NAGE) EBT (2010 - 2026)

Niagen Bioscience (NAGE) has reported EBT for 17 consecutive years, with $6.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBT rose 28.75% year-over-year to $6.7 million; the TTM figure through Mar 2026 stood at $19.7 million (up 35.11% YoY), while the FY2025 annual figure was $18.2 million, up 105.44% from the prior year.
• EBT advanced to $6.7 million in Q1 2026 per NAGE's latest filing, from $4.4 million in the prior quarter.
• Across five years, EBT topped out at $7.5 million in Q4 2024 and bottomed at -$11.7 million in Q2 2022.
• Historically, EBT has averaged -$878235.3 across 5 years, with a median of -$270000.0 in 2023.
• On a YoY basis, EBT climbed as much as 25013.33% in 2025 and fell as far as 40.89% in 2025.
• Niagen Bioscience's EBT stood at -$1.6 million in 2022, then surged by 82.9% to -$270000.0 in 2023, then jumped by 2871.85% to $7.5 million in 2024, then slumped by 40.89% to $4.4 million in 2025, then jumped by 52.24% to $6.7 million in 2026.
• Business Quant data shows NAGE's EBT at $6.7 million in Q1 2026, $4.4 million in Q4 2025, and $4.8 million in Q3 2025.